Novel glucose-lowering agents that benefit diabetic foot: icing on the cake
The prevalence of diabetes mellitus is increasing and is linked to several complications, including diabetic foot. Novel glucose-lowering agents are sought that also have beneficial effects in reducing diabetic complications. Among the novel glucose-lowering agents demonstrating clinical promise, th...
Saved in:
| Main Authors: | Qin Li, Shiyan Yu, Shunli Rui, Xiaobu Lin, Yi Yuan, David G. Armstrong, Yi Xu, Wuquan Deng |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-07-01
|
| Series: | Frontiers in Endocrinology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2025.1581403/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Comparison of New‐Onset Peripheral Artery Disease in Patients With Type 2 Diabetes Exposed to Sodium–Glucose Cotransporter‐2 Inhibitors, Dipeptidyl Peptidase‐4 Inhibitors, or Glucagon‐Like Peptide‐1 Agonists: A Population‐Based Cohort Study
by: Oscar Hou‐In Chou, et al.
Published: (2025-06-01) -
The impact of innovative glucose-lowering drugs on the course and outcome of COVID-19 in patients with type 2 diabetes mellitus
by: T. N. Markova, et al.
Published: (2024-05-01) -
Sodium-glucose cotransporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors on diabetic macular edema and the need for intravitreal injection
by: Yoo-Ri Chung, et al.
Published: (2025-07-01) -
Analysing the Shift in Prescribing Patterns: Sodium Glucose Co-transporter 2 Inhibitors, Dipeptidyl Peptidase 4 Inhibitors and Traditional Antidiabetic Drugs
by: Vini Pavithran, et al.
Published: (2025-04-01) -
Sodium-glucose cotransporter 2 inhibitor for the treatment of diabetic nephropathy
by: Kong Ling-li, et al.
Published: (2021-01-01)